Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2008 Fourth Quarter and Full Year Results



    
                         Tuesday, February 17, 2009
                                9:00 a.m. EST

                               1-800-732-6179

                Webcast: http://www.nucryst.com/web_casts.htm
    

    PRINCETON, NJ, Feb. 9 /CNW/ - NUCRYST Pharmaceuticals Corp. invites
analysts and investors to participate in a briefing on Tuesday, February 17,
2009, with David B. Holtz, Interim President & Chief Executive Officer, and
Chief Financial Officer, regarding the Company's 2008 fourth quarter and full
year results.
    The briefing, via conference call, is set for 9:00 a.m. EST. To
participate, please call the toll-free number 1-800-732-6179. In addition to
standard disclosure over wire services, a news release with the fourth quarter
and full year financial results will be posted on the NUCRYST web site prior
to the call. To listen to the call live on the Internet, please go to
http://www.nucryst.com/web_casts.htm.
    The briefing will be recorded and available for re-broadcast on demand
for seven days by dialing 1-877-289-8525. Callers will need to provide the
operator with the following reservation number: 21297480 followed by the
number sign. An audio file of the call will also be archived on the NUCRYST
web site.

    About NUCRYST Pharmaceuticals

    NUCRYST Pharmaceuticals Corp. (NASDAQ:   NCST; TSX: NCS) develops,
manufactures and commercializes medical products that fight infection and
inflammation using SILCRYST(TM), its patented atomically disordered
nanocrystalline silver technology. NUCRYST licensed world-wide rights for
SILCRYST(TM) wound care coating products to Smith & Nephew plc, which markets
these products in over 30 countries under their Acticoat(TM) trademark.
NUCRYST is also developing pharmaceutical products to address medical
conditions that are characterized by pain, infection and inflammation. The
Company has developed its proprietary nanocrystalline silver in a powder form,
referred to as NPI 32101 for use in medical devices and as an active
pharmaceutical ingredient.

    
    Acticoat(TM) is a trademark of Smith & Nephew plc
    SILCRYST(TM) is a trademark of NUCRYST Pharmaceuticals Corp.
    

    %SEDAR: 00023031E




For further information:

For further information: David Wills, Gillian McArdle, Investor
Relations, NUCRYST Pharmaceuticals Corp., (416) 504-8464, info@nucryst.com

Organization Profile

NUCRYST PHARMACEUTICALS CORP.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890